Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Nov 2019 15:30

RNS Number : 7019S
Redx Pharma plc
07 November 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Redx Pharma Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Aviva plc & its subsidiaries

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

Registered Holder:

Chase (GA Group) Nominees Limited 6,609,094*

HSBC Global Custody Nominee (UK) Limited 2,086,725*

State Street Nominees Limited 62,999*

*denotes direct interest

 

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

06/11/2019

6. Date on which issuer notified (DD/MM/YYYY):

07/11/2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

6.93%

6.93%

126,477,914

Position of previous notification (if

applicable)

8.416%

8.416%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary SharesGB00BSNB6S51

8,758,818

6.93%

SUBTOTAL 8. A

8,758,818

6.93%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aviva plc

6.93%

6.93%

Aviva Group Holdings Limited

6.93%

6.93%

Aviva Investors Holdings Limited

6.93%

6.93%

Aviva Investors Global Services Limited

6.93%

6.93%

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

This notification is prompted by a 7% to 6% change at Direct Interest Level (Box 8A)

 

Place of completion

Norwich, England

Date of completion

07 November 2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLBUBDBIDGBGCR
Date   Source Headline
3rd Jan 20197:00 amRNSRedx to present at 2019 Biotech Showcase event
28th Dec 201811:47 amRNSPublication of Annual Report and Accounts
30th Nov 20188:45 amEQSHardman & Co Research: RedX Pharma (REDX): RXC006: First fibrosis development candidate
30th Nov 20187:00 amRNSFirst RXC006 data for treatment of fibrosis
27th Nov 20184:05 pmEQSHardman & Co Research: Redx Pharma (REDX): Streamlined, focused and good value
19th Nov 20187:00 amRNSCFO Announcement
19th Nov 20187:00 amRNSPreliminary Results for year ended 30 Sept 2018
14th Nov 20187:00 amRNSRedx announces new drug development candidate
9th Nov 20189:51 amEQSHardman & Co Research: Redx Pharma (REDX):ROCK2 inhibitors in chronic kidney disease
5th Nov 20187:00 amRNSPreclinical data presented at cancer conference
31st Oct 20187:00 amRNSNotice of Results
29th Oct 20187:00 amRNSRedx notes election of Lisa Anson to UK BIA BOD
26th Oct 20187:00 amRNSDetails from Redx ROCK2 inhibitor poster
22nd Oct 20187:00 amRNSRedx ROCK2 inhibitors poster to be presented
2nd Oct 20181:40 pmEQSHardman & Co Research: Redx Pharma (REX): Strategy launch
6th Sep 20187:15 amEQSHardman & Co Research: Redx Pharma (REDX): Back to the clinic
4th Sep 20187:00 amRNSRedx Pharma Announces Way Forward For RXC004
18th Jun 20187:15 amEQSHardman & Co Research: Redx Pharma (REDX): 'Focus, Realism and Results' - Ian Ross, Chairman
4th Jun 20187:00 amRNSDirectorate Update and Grant of Options
30th May 20187:00 amRNSInterim Results
15th May 201812:00 pmEQSHardman & Co Research: Redx Pharma (REDX): Clinical and corporate update
25th Apr 201810:57 amRNSShare Purchase by Chairman
25th Apr 20189:05 amRNSSecond Price Monitoring Extn
25th Apr 20189:00 amRNSPrice Monitoring Extension
24th Apr 20187:00 amRNSRedx Appoints Senior AstraZeneca Executive as CEO
13th Apr 20188:19 amRNSHolding(s) in Company
12th Apr 201811:28 amRNSHolding(s) in Company
29th Mar 20187:00 amRNSRXC004 Clinical Trial Update
22nd Mar 20187:00 amRNSRedx and Deinove sign option and licence agreement
15th Mar 20187:00 amRNSPoster Presentation at AACR Annual Meeting
6th Mar 20184:33 pmRNSResult of AGM
12th Feb 201810:23 amRNSPosting of Annual Accounts & AGM notice
6th Feb 20187:00 amRNSFirst Patient Dosed in Phase 1/2a Trial of RXC004
22nd Jan 20187:00 amRNSAppointment of Chief Medical Officer
28th Dec 201711:28 amRNSHolding(s) in Company
27th Dec 20175:45 pmRNSShare Purchase by Directors
22nd Dec 20177:00 amRNSGrant of Options
20th Dec 20177:00 amRNSFinal Results for the Year Ended 30 September 2017
14th Dec 20173:56 pmRNSHolding(s) in Company
8th Dec 20175:04 pmRNSHolding(s) in Company
14th Nov 201711:30 amRNSDirector/PDMR Shareholding
13th Nov 20177:15 amRNSHardman Research: Streamlined and clean
6th Nov 201712:00 pmRNSRestoration - Restoration Redx Pharma plc
6th Nov 20177:00 amRNSRedx updates strategy and resumes shares trading
27th Oct 20178:00 amRNSUpdate on Application to the High Court
13th Oct 20177:00 amRNSUpdate on Court Process
31st Aug 20179:00 amRNSRedx to present new scientific data at ESMO 2017
24th Aug 20179:42 amRNSDistribution to Unsecured Creditors
14th Aug 201710:05 amRNSDirectorate Change
10th Aug 20178:00 amRNSPublication of Joint Administrators' Proposals

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.